Research programme: TransKingdom RNA interference therapeutics - Marina Biotech

Drug Profile

Research programme: TransKingdom RNA interference therapeutics - Marina Biotech

Alternative Names: tkRNAi therapeutic targeting beta-catenin (CTNNB1) - Marina Biotech; CEQ 400; CEQ 600; CEQ 700; CEQ-501; CEQ-626; CEQ608; CEQ609; CEQ621; CEQ631; CEQ632; tk RNAi; TransKingdom RNA interference

Latest Information Update: 28 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cequent Pharmaceuticals
  • Developer Marina Biotech
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Familial adenomatous polyposis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Human papillomavirus infections; Inflammatory bowel diseases

Most Recent Events

  • 28 May 2018 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO)
  • 31 Dec 2017 Pharmacodynamics data from a preclinical trial in Inflammatory bowel disease released by Marina Biotech
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top